Varespladib

Drug Profile

Varespladib

Alternative Names: A-001; A-002; LY-315920; LY-333013; S-3013; S-5920; Varespladib methyl

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Shionogi
  • Developer Anthera Pharmaceuticals; University Health Network
  • Class Acetic acids; Anti-inflammatories; Antirheumatics; Indoles; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury

Highest Development Phases

  • Discontinued Acute coronary syndromes; Acute lung injury; Coronary artery disease; Multiple organ failure; Systemic inflammatory response syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Australia (PO)
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top